Cochrane · systematic review · CD002064
Recombinant human insulin‐like growth factor I (rhIGF‐I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease
Beauverd, M, Mitchell, JD, Wokke, JHJ, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
NeuromuscularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 5 · 100%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: patients with amyotrophic lateral sclerosis/motor neuron disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
rhIGF‐I, 0.1 mg/kg/day ‐ survival at12 months | no estimate extracted | 3 studies · 690 participants | Low |
rhIGF‐I, 0.1 mg/kg/day ‐ change in AALSRS at 9 months | no estimate extracted | 2 studies · 357 participants | Low |
rhIGF‐I, 0.1 mg/kg/day ‐ change in SIP after 9 months | no estimate extracted | 156 participants | Low |
rhIGF‐I, all doses ‐ injection site pain | no estimate extracted | 2 studies · 449 participants | Low |
rhIGF‐I, all doses ‐ injection site inflammation/reaction | no estimate extracted | 3 studies · 779 participants | Low |